IMEIK(SZ:300896)2023-03-08 16:00Dividend Distribution - The company plans to distribute a cash dividend of 28 RMB per 10 shares to all shareholders, based on a total of 216,360,000 shares[3]. - A cash dividend of CNY 28 per 10 shares was proposed, totaling CNY 605.81 million, which represents 47.94% of the net profit attributable to shareholders[149]. - The total cash dividend amount accounted for 100% of the total distributable profit[148]. Financial Performance - The company's operating revenue for 2022 was ¥1,938,838,363.70, representing a 33.91% increase compared to the previous year[12]. - The net profit attributable to shareholders for 2022 was ¥1,263,558,415.71, reflecting a growth of 31.90% year-over-year[12]. - The net profit after deducting non-recurring gains and losses was ¥1,197,352,350.70, which is a 30.92% increase from the previous year[12]. - The net cash flow from operating activities reached ¥1,193,935,203.61, marking a 26.64% increase compared to 2021[12]. - The total assets at the end of 2022 amounted to ¥6,258,547,700.17, an 18.71% increase from the end of 2021[12]. - The net assets attributable to shareholders at the end of 2022 were ¥5,846,126,232.19, showing a 16.24% increase year-over-year[12]. - The company reported a basic and diluted earnings per share of ¥5.84, which is a 31.83% increase from the previous year[12]. Market Position and Growth - The company holds a 21.3% market share in the domestic market for sodium hyaluronate-based dermal fillers, ranking first among domestic manufacturers[21]. - The medical beauty market in China has a compound annual growth rate (CAGR) of 17.5% from 2017 to 2021, significantly outpacing the global market[20]. - The company anticipates continued high growth potential in the medical beauty market, as China's penetration rate remains significantly lower than that of mature markets[20]. - The company has observed a trend of domestic products replacing imported products in the medical beauty industry, leading to an increase in market share for local manufacturers[20]. Research and Development - Research and development investment accounted for 8.93% of total revenue, with a year-on-year increase of 69.20% in R&D spending[26]. - The company has accumulated 49 patents, with 25 being invention patents, and 25.39% of its total workforce engaged in R&D[27]. - The company is currently conducting clinical trials for several innovative products, including a gel for correcting chin retrusion and a type A botulinum toxin for improving glabellar lines[26]. - The company has successfully commercialized a series of dermal fillers based on sodium hyaluronate and polylactic acid, as well as facial implant lines[23]. Strategic Initiatives - The company’s future strategies include market expansion and potential mergers and acquisitions, although specific details are not disclosed[3]. - The company has strengthened its strategic layout in weight management and fat reduction, with a focus on the deoxycholic acid injection project and a collaboration with Beijing Zhitai Biopharmaceutical Technology Co., Ltd. for the semaglutide injection project, which is currently in preclinical research[27]. - The company has become the exclusive distributor of HUTOX botulinum toxin in China, enhancing its product pipeline and competitive strength in the botulinum toxin category[27]. Corporate Governance - The company’s governance structure complies with relevant laws and regulations, ensuring independent operation without interference from controlling shareholders[114]. - The company has established a transparent performance evaluation and incentive mechanism, with a dedicated remuneration and assessment committee[112]. - The company has a complete and independent production and operational system, with no instances of asset guarantees or resource occupation by controlling shareholders reported during the reporting period[114]. Environmental Responsibility - The company installed a new wastewater treatment system in April 2022, significantly reducing water pollutant emissions[158]. - Air pollution control measures include organized emissions and regular inspections, ensuring compliance with national and local environmental standards[158]. - The company is committed to ongoing environmental education and training for employees, with two sessions held in 2022[159]. Employee Development - The company conducted 4 new employee training sessions covering 340 individuals, with an average course quality evaluation score of 4.8[145]. - The employee coverage rate for training programs reached 65%, with a total of 8,346 learning instances recorded[145]. - The company has established a flexible salary system linked to performance, ensuring employee interests are protected[143]. Future Outlook - The company provided guidance for 2023, projecting a revenue growth of 20% to reach approximately 1.8 billion RMB[125]. - The company plans to enhance R&D investment in 2023, focusing on biomedical materials and expanding into biomedicine, aiming to strengthen its technological leadership and enrich its product line[101]. - The management emphasized a commitment to sustainability, aiming for a 50% reduction in carbon emissions by 2025[125].